Eli Lilly Moves Closer To Another Weight-Loss Drug: Retatrutide Clears Two More Phase 3 Trials Ahead Of FDA Filing

Eli Lilly's retatrutide, a once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, met the primary endpoint in the Triumph-2 and Triumph-3 Phase 3 studies.

Retatrutide is moving closer to FDA filing for weight loss after clearing two more Phase 3 trials.

The drug targets GIP, GLP-1, and glucagon receptors to promote weight loss.